← Eichor
Condition: Resectable Lung Non Small Cell Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Resectable Lung Non Small Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
NA · 1 location(s) · Chang Gung Memorial Hospital · NCT06262386IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in No
Phase N/A · 1 location(s) · Bristol-Myers Squibb · NCT06169956A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05377658Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Phase 2 · 1 location(s) · The First Affiliated Hospital of Guangzhou Medical Universit · NCT06926790Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After R
Phase N/A · 1 location(s) · Liaoning Cancer Hospital & Institute · NCT06109454Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT04324151TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Phase 2 · 1 location(s) · Beijing Chest Hospital, Capital Medical University · NCT06467617Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer
NA · 6 location(s) · University Hospital, Ghent · NCT06057766Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Phase N/A · 22 location(s) · Fundación GECP · NCT06634199A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Phase 3 · 7 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04316364Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Phase 2 · 5 location(s) · University Hospital, Bonn · NCT06810609Pathological Response After Neoadjuvant Treatment on NSCLC
Phase N/A · 17 location(s) · Fundación GECP · NCT05167487A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Parti
Phase 3 · 267 location(s) · Merck Sharp & Dohme LLC · NCT06312137Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Phase 1/Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06088771Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06924398IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Phase 2 · 30 location(s) · Innate Pharma · NCT05742607Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell
Phase 2 · 4 location(s) · University Hospital, Essen · NCT06784791Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling
NA · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06276530D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage II
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT07016126A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable
Phase N/A · 9 location(s) · Ono Pharmaceutical Co., Ltd. · NCT07169708A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05104788Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among A
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07584239Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harbor
Phase 3 · 199 location(s) · Boehringer Ingelheim · NCT07195695Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
Phase 2 · 1 location(s) · Medical University Innsbruck · NCT04875585Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06734182Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
Phase 2 · 1 location(s) · Konkuk University Medical Center · NCT05469022
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.